Anthem (NASDAQ:ANTX) Insider Joshua Eizen Sells 2,826 Shares of Company Stock

Anthem, Inc. (NASDAQ:ANTX) insider Joshua Eizen sold 2,826 shares of the business’s stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $4.22, for a total transaction of $11,925.72. Following the completion of the sale, the insider directly owned 207,546 shares in the company, valued at $875,844.12. This trade represents a 1.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Anthem Trading Up 1.3%

Anthem stock traded up $0.05 during midday trading on Friday, reaching $4.00. 240,356 shares of the stock traded hands, compared to its average volume of 317,730. Anthem, Inc. has a 12-month low of $1.00 and a 12-month high of $7.19. The firm has a market cap of $150.96 million, a PE ratio of -3.74 and a beta of -0.93. The company has a 50-day simple moving average of $4.74 and a two-hundred day simple moving average of $4.11.

Anthem (NASDAQ:ANTX) last released its earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter.

Hedge Funds Weigh In On Anthem

Several large investors have recently added to or reduced their stakes in the business. Vivo Capital LLC acquired a new stake in Anthem during the 1st quarter worth approximately $10,785,000. Seven Fleet Capital Management LP purchased a new position in Anthem in the first quarter valued at approximately $683,000. Commodore Capital LP acquired a new position in Anthem during the first quarter valued at approximately $7,981,000. Spruce Street Capital LP acquired a new position in Anthem during the first quarter valued at approximately $5,576,000. Finally, Ally Bridge Group NY LLC acquired a new position in Anthem during the first quarter valued at approximately $1,800,000. 90.47% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ANTX has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anthem in a research note on Friday, October 2nd. Guggenheim started coverage on shares of Anthem in a report on Monday, July 20th. They issued a “buy” rating and a $9.00 target price for the company. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $9.00.

Anthem Company Profile

An2 Therapeutics, Inc is a clinical-stage biopharmaceutical company that traded on the Nasdaq under the symbol ANTX. The company focused on developing novel treatments for serious infectious diseases, with its lead candidate, epetraborole, designed as an oral therapy for pulmonary disease caused by nontuberculous mycobacteria (NTM).

Epetraborole was evaluated in clinical studies involving patients with refractory Mycobacterium avium complex pulmonary disease, a difficult-to-treat infection that primarily affects the lungs.